1. In Vivo
  2. >>Business Strategy

Drug Discount Programs Create More Cloud In Quest For Transparency

 
• By Sarah Karlin-Smith

Behind a popular drug discount program are pharmacy benefits managers and even drug companies themselves, raising questions about whether such businesses may yet be another player in an opaque and complicated supply chain that is facilitating higher US drug prices, even as the most prominent company in the space, GoodRx, routinely criticizes soaring list prices. 

Clouds

Since 2011, GoodRx has operated a web- and mobile app-based business that lets consumers search for the best cash-based deals on prescription drugs. Enter a drug name and zip code, and voila, you get a list of nearby pharmacies and the discount that GoodRx coupons can get you on the product at various locations, including via mail-order.

The aim is typically to help uninsured patients or those in high-deductible health plans access drugs at more affordable prices...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

CellProthera Targeting Heart Regeneration Where No Treatment Exists

 
• By David Wild

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

Patient-Centric Strategy Drives Memo Therapeutics Forward

 
• By Anabel Costa-Ferreira

Memo Therapeutics is sharpening its focus on its lead antibody Potravitug, for BK polyomavirus (BKPyV) in kidney transplant patients as it prepares for Phase III trials and doubles down on patient engagement.

How Rare Disease Advocates Are Reshaping Gene Therapy Development

 
• By David Wild

Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.

Small Biotech, Big Breakthrough: Abivax Enters A New Era

 
• By Lucie Ellis-Taitt

Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.

More from In Vivo

Execs On The Move: October 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

A $30m Milestone And Leadership Handoff Signal New Chapter For Recursion

 
• By David Wild

Recursion recently announced the completion of a $30m microglia map and named Najat Khan as CEO, replacing co-founder Chris Gibson.

How Rare Disease Advocates Are Reshaping Gene Therapy Development

 
• By David Wild

Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.